32 
gress, the President and the appropriate Federal agencies regarding 
Federal action which the Commission determines should be taken to 
promote, regulate or study activities involving genetic manipulation. 
It is the committee’s intent that the final report of the Commission be 
published and made available to the public. 
204 .( 0 ) . Termination of the Commission 
The Commission shall terminate within 60 days of the date upon 
which it has completed its studies and submits its final report to Con- 
gress, the President and the appropriate Federal agencies. 
INFLATION IMPACT STATEMENT 
The committee anticipates that the enactment of H.R. 11192 will 
have a negligible impact on inflation in the biomedical research area 
and in Federal spending. As determined by the Congressional Budget 
Office, the cost to the government of expanding the scope of the NIH 
Guidelines governing recombinant DNA activity to encompass all 
such activity regardless of its funding source would be less than $3 
million annually. In view of the potential hazards to the public health 
and the environment from improperly conducted recombinant DNA 
activities and the potential benefits to society which may derive from 
such 'activities, the minimal increases in expenses which may accrue to 
entities engaged in recombinant DNA activities in connection with 
compliance with the requirements of the proposed legislation are 
wholly appropriate. 
CONGRESSIONAL BUDGET OFFICE COST ESTIMATE 
A cost estimate was requested on H.R. 11192 when it was ordered 
reported from the Committee on Interstate and Foreign Commerce, 
and the Congressional Budget Office has provided the following 
information. 
Congressional Budget Office, 
U.S. Congress, 
Washington , D.C., March 23, 1978. 
Hon. Harley O. Staggers, 
Chairman , Committee on Interstate and Foreign Com/merce , 
U.S. House of Representatives , 
W ashington, D.C. 
Dear Mr. Chairman : Pursuant to Section 403 of the Congressional 
Budget Act of 1974, the Congressional Budget Office has prepared 
the attached cost estimate for H.R. 11192, a bill to extend for two 
years the scope of the containment requirements of the experimental 
guidelines of the National Institutes of Health respecting recombinant 
DNA research to include all public and private recombinant DNA 
activities and to provide for a study respecting research and technol- 
ogy involving genetic manipulation. _ . 
Should the Committee so desire, we would be pleased to provide 
further details on the attached cost estimate. 
Sincerely, 
Alice M. Rivlin, 
Director, 
[Appendix B — 162] 
